Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746669 | 0.83 | MAOB (0.57) | MAOBBACE1ESR1ESR2MAPT | |
| SCHEMBL13294876 | 0.78 | ACHE (0.60) | MAPTCYP3A4ALDH1A1KDM4EHPGD | |
| SCHEMBL21780871 | 0.77 | BACE1 (0.47) | MAOBBACE1MAPTCYP3A4ALDH1A1 | |
| SCHEMBL11612722 | 0.77 | CA12 (0.58) | MAPTCYP3A4ALDH1A1LMNAGAA | |
| SCHEMBL2089252 | 0.77 | CYP1A1 (0.44) | MAPTALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL16562813 | 0.75 | MEN1 (0.51) | MAPTALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL4180414 | 0.75 | IDO1 (0.42) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2481401 | 0.75 | HSD17B10 (0.36) | MAOBESR1ESR2MAPTCYP3A4 | |
| SCHEMBL30514387 | 0.75 | MAOB (0.70) | MAOBESR1ESR2MAPTCYP3A4 | |
| SCHEMBL119396 | 0.75 | MAOB (0.70) | MAOBESR1ESR2MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2691375-B1 | SUBSTITUTED BENZIMIDAZOLES AS MPS-1 KINASE INHIBITORS | BAYER IP GMBH (DE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2012130905-A1 | SUBSTITUTED BENZIMIDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | WO | disclosed |
| US-7129234-B2 | Phenyl heterocyclyl ethers | PFIZER INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1377550-B9 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| EP-1377550-B1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| EP-1377550-A1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1268396-A1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002083643-A1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-24 | — | — | WO | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
| WO-2001072687-A1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | MAOB 1274/4885BACE1 3704/4885ESR1 1203/4885 |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | MAOB 1674/4885BACE1 2392/4885ESR1 260/4885 |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | MAOB 1674/4885BACE1 2392/4885ESR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.